Nelson A Rodriguez1, Francisco J Ascaso. Show Affiliations » 1. Hospital of Navarra, Pamplona, Spain.
Abstract
Entities: Chemical Disease
Mesh: See more » Adenocarcinoma/drug therapyAdenocarcinoma/secondaryAgedAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useBevacizumabCetuximabColorectal Neoplasms/drug therapyCombined Modality TherapyDisease ProgressionErbB Receptors/antagonists & inhibitorsErbB Receptors/physiologyEyelashes/drug effectsFemaleFluorouracil/administration & dosageHair Color/drug effectsHepatectomyHumansHypertrichosis/chemically inducedLeucovorin/administration & dosageLiver Neoplasms/drug therapyLiver Neoplasms/secondaryLiver Neoplasms/surgeryNeoplasm Proteins/antagonists & inhibitorsOrganoplatinum Compounds/administration & dosageOxaliplatin
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsNeoplasm ProteinsOrganoplatinum CompoundsOxaliplatinBevacizumabEGFR protein, humanErbB ReceptorsCetuximabLeucovorinFluorouracil
Year: 2011 PMID: 21483009 DOI: 10.1200/JCO.2011.34.6858
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544